Monopar Therapeutics Inc. (MNPR) vs Prime Medicine, Inc. (PRME)

Monopar Therapeutics Inc. and Prime Medicine, Inc. are both Biotechnology companies. Monopar Therapeutics Inc. and Prime Medicine, Inc. are of similar size ($609.4M and $602.8M). Monopar Therapeutics Inc. has the higher net margin (0.00% vs −4,613.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Monopar Therapeutics Inc. leads on 10 and Prime Medicine, Inc. on 1.

Valuation

Metric MNPR PRME Biotechnology median
P/E n/m n/m 7.88
P/S n/m 126.19 11.47
P/B 5.56 12.91 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 102.84 10.73
Earnings yield (2.55%) (37.01%) (28.84%)
Free cash flow yield (1.67%) (30.52%) (23.03%)

Profitability

Metric MNPR PRME Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (4,824.94%) 0.00%
Net margin 0.00% (4,613.11%) 0.00%
Free cash flow margin 0.00% (3,850.92%) 0.00%
Return on equity (19.50%) (373.29%) (57.72%)
Return on assets (18.90%) (71.16%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MNPR PRME Biotechnology median
Revenue growth (TTM) — (17.90%) 5.64%
EPS growth (last fiscal year) 54.99% 18.18% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MNPR PRME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 33.56 3.05 4.73
Net debt to EBITDA 8.06 0.88 0.96

Dividend

Metric MNPR PRME Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric MNPR PRME Biotechnology median
Market cap 602.75m 609.43m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack